In this study The findings from this study provide a good natural history of patients who underwent intervention for CLTI. No one is surprised that the authors reported smoking, renal failure, Rutherford class ≥5, and below-the-knee arterial disease are significant predictors of amputation. Recent global guidelines have provided strong evidence to treat all patients with an antiplatelet agent and to use moderate- or high-intensity statin therapy to reduce all-cause and cardiovascular mortality.1 However, interestingly, the authors found that two other drugs not commonly used in the United States helped prevent amputation and arterial restenosis. In this study, the administration of iloprost (a synthetic of the vasodilator prostacyclin) and cilostazol was left to the operator’s preference. Iloprost (Endoprost; Italfarmaco SpA, Milan, Italy) was typically administered starting the first day after revascularization for ≤4 to 7 days after the procedure at an intravenous infusion rate of 6 to 16 h/d. In a different study, cilostazol (Pletal/Fripass; Italfarmaco SpA) was prescribed at 100 mg orally two times daily combined with cilostazol and resulted in a significant.
Reference link- https://www.jvascsurg.org/article/S0741-5214(21)00224-X/fulltext
